Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Najat Khan Sells 23,588 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Najat Khan sold 23,588 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $3.58, for a total transaction of $84,445.04. Following the completion of the sale, the chief executive officer directly owned 2,175,796 shares of the company’s stock, valued at approximately $7,789,349.68. This trade represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Najat Khan also recently made the following trade(s):

• On Monday, March 9th, Najat Khan sold 28,298 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.35, for a total transaction of $94,798.30.

Recursion Pharmaceuticals Trading Down 12.6%

Shares of NASDAQ:RXRX traded down $0.48 during trading on Friday, reaching $3.32. 26,796,919 shares of the company were exchanged, compared to its average volume of 17,402,092. The business’s fifty day simple moving average is $3.30 and its 200-day simple moving average is $3.82. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.47 and a quick ratio of 5.47. Recursion Pharmaceuticals, Inc. has a 12-month low of $2.77 and a 12-month high of $7.18. The firm has a market capitalization of $1.76 billion, a PE ratio of -2.77 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The company had revenue of $6.47 million for the quarter, compared to analysts’ expectations of $15.78 million. During the same quarter in the prior year, the firm earned ($0.50) earnings per share. Recursion Pharmaceuticals’s revenue was down 56.8% compared to the same quarter last year. On average, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.02 EPS for the current year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. International Assets Investment Management LLC purchased a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $31,000. Integral Investment Advisors Inc. purchased a new stake in Recursion Pharmaceuticals during the 1st quarter worth approximately $39,000. Sequoia Financial Advisors LLC acquired a new position in Recursion Pharmaceuticals during the 4th quarter valued at approximately $41,000. MQS Management LLC acquired a new position in Recursion Pharmaceuticals during the 1st quarter valued at approximately $41,000. Finally, Allworth Financial LP raised its holdings in shares of Recursion Pharmaceuticals by 85.6% in the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after buying an additional 4,403 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Wall Street Analysts Forecast Growth

RXRX has been the subject of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. JPMorgan Chase & Co. reduced their price target on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Wall Street Zen cut Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Bank of America cut their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.10.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.